A Study of WX390 in Patients With Advanced Solid Tumors

Summary

The goal of this clinical trial is to evaluate the efficacy and safety of WX390 in patients with advanced solid tumors. The main questions it aims to answer are: * PFS, OS, DoR at week 48; * antitumor effects at week 24 and week 48. Participants will be treated with WX390 orally, and follow the efficacy and safety evaluation according to the protocol.

Timeline

Start

2021-05-11

Primary completion

2025-06-12

Completion

2026-06-12

Drugs

Indications